Cargando…
Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients
INTRODUCTION: Platelets are one factor promoting tumor development. Conversely, lymphocytes are one factor for immune protection. The peripheral blood platelets–lymphocyte ratio (PLR) is useful as an inflammation/immune indicator to predict postoperative recurrence and prognosis of a variety of mali...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039245/ https://www.ncbi.nlm.nih.gov/pubmed/32110104 http://dx.doi.org/10.2147/CMAR.S241069 |
_version_ | 1783500788572618752 |
---|---|
author | Ohe, Yuka Fushida, Sachio Yamaguchi, Takahisa Kinoshita, Jun Saito, Hiroto Okamoto, Koichi Nakamura, Keishi Tajima, Hidehiro Ninomiya, Itasu Ohta, Tetsuo |
author_facet | Ohe, Yuka Fushida, Sachio Yamaguchi, Takahisa Kinoshita, Jun Saito, Hiroto Okamoto, Koichi Nakamura, Keishi Tajima, Hidehiro Ninomiya, Itasu Ohta, Tetsuo |
author_sort | Ohe, Yuka |
collection | PubMed |
description | INTRODUCTION: Platelets are one factor promoting tumor development. Conversely, lymphocytes are one factor for immune protection. The peripheral blood platelets–lymphocyte ratio (PLR) is useful as an inflammation/immune indicator to predict postoperative recurrence and prognosis of a variety of malignancies. The peripheral blood neutrophil–lymphocyte ratio (NLR) has also been reported as a useful inflammation/immune indicator. However, there are few studies evaluating the relationship between these peripheral blood indicators and the effectiveness of chemotherapy. Thus, we examined these relationships in gastric cancer patients. PATIENTS AND METHODS: Between 2005 and 2018, 41 gastric cancer patients treated with preoperative DCS therapy (docetaxel, cisplatin, and S-1) therapy followed by gastrectomy were evaluated. Data for peripheral blood tests prior to the initiation of chemotherapy were used. The effectiveness of chemotherapy was determined using Response Evaluation Criteria in Solid Tumors (RECIST) and the pathological response of primary lesions (Ef grade). The relationship between the blood test results and the effectiveness of chemotherapy was evaluated. RESULTS: Each optimal cut-off value of peripheral inflammation/immune indicators was calculated through ROC curves. Although the pathological responder (Ef grade 2 or 3) revealed significantly better prognosis than the non-responder (Ef grade 0-1b), no relationship was found between responder according to RECIST and prognosis (P=0.014, P=0.992). In univariate analysis, a low PLR (<180, P=0.005), low NLR (<2.6, P=0.019), high lymphocyte (≥1.43, P=0.019) and high PNI (≥40, P=0.032) were identified as prognostic markers, whereas PLR was the only marker correlated with pathological response (P=0.031). CONCLUSION: PLR obtained prior to chemotherapy might be a useful indicator for predicting chemosensitivity owing to the simplicity of its procedure. |
format | Online Article Text |
id | pubmed-7039245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-70392452020-02-27 Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients Ohe, Yuka Fushida, Sachio Yamaguchi, Takahisa Kinoshita, Jun Saito, Hiroto Okamoto, Koichi Nakamura, Keishi Tajima, Hidehiro Ninomiya, Itasu Ohta, Tetsuo Cancer Manag Res Original Research INTRODUCTION: Platelets are one factor promoting tumor development. Conversely, lymphocytes are one factor for immune protection. The peripheral blood platelets–lymphocyte ratio (PLR) is useful as an inflammation/immune indicator to predict postoperative recurrence and prognosis of a variety of malignancies. The peripheral blood neutrophil–lymphocyte ratio (NLR) has also been reported as a useful inflammation/immune indicator. However, there are few studies evaluating the relationship between these peripheral blood indicators and the effectiveness of chemotherapy. Thus, we examined these relationships in gastric cancer patients. PATIENTS AND METHODS: Between 2005 and 2018, 41 gastric cancer patients treated with preoperative DCS therapy (docetaxel, cisplatin, and S-1) therapy followed by gastrectomy were evaluated. Data for peripheral blood tests prior to the initiation of chemotherapy were used. The effectiveness of chemotherapy was determined using Response Evaluation Criteria in Solid Tumors (RECIST) and the pathological response of primary lesions (Ef grade). The relationship between the blood test results and the effectiveness of chemotherapy was evaluated. RESULTS: Each optimal cut-off value of peripheral inflammation/immune indicators was calculated through ROC curves. Although the pathological responder (Ef grade 2 or 3) revealed significantly better prognosis than the non-responder (Ef grade 0-1b), no relationship was found between responder according to RECIST and prognosis (P=0.014, P=0.992). In univariate analysis, a low PLR (<180, P=0.005), low NLR (<2.6, P=0.019), high lymphocyte (≥1.43, P=0.019) and high PNI (≥40, P=0.032) were identified as prognostic markers, whereas PLR was the only marker correlated with pathological response (P=0.031). CONCLUSION: PLR obtained prior to chemotherapy might be a useful indicator for predicting chemosensitivity owing to the simplicity of its procedure. Dove 2020-02-20 /pmc/articles/PMC7039245/ /pubmed/32110104 http://dx.doi.org/10.2147/CMAR.S241069 Text en © 2020 Ohe et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Ohe, Yuka Fushida, Sachio Yamaguchi, Takahisa Kinoshita, Jun Saito, Hiroto Okamoto, Koichi Nakamura, Keishi Tajima, Hidehiro Ninomiya, Itasu Ohta, Tetsuo Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients |
title | Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients |
title_full | Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients |
title_fullStr | Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients |
title_full_unstemmed | Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients |
title_short | Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients |
title_sort | peripheral blood platelet–lymphocyte ratio is good predictor of chemosensitivity and prognosis in gastric cancer patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039245/ https://www.ncbi.nlm.nih.gov/pubmed/32110104 http://dx.doi.org/10.2147/CMAR.S241069 |
work_keys_str_mv | AT oheyuka peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients AT fushidasachio peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients AT yamaguchitakahisa peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients AT kinoshitajun peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients AT saitohiroto peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients AT okamotokoichi peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients AT nakamurakeishi peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients AT tajimahidehiro peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients AT ninomiyaitasu peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients AT ohtatetsuo peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients |